Profile data is unavailable for this security.
About the company
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.
- Revenue in USD (TTM)5.40bn
- Net income in USD2.08bn
- Incorporated1989
- Employees3.00k
- LocationVertex Pharmaceuticals Inc50 Northern AveBOSTON 02210-1862United StatesUSA
- Phone+1 (617) 341-6393
- Websitehttps://www.vrtx.com/
Mergers & acquisitions
| Acquired company | VRTX:NSQ since announced | Transaction value |
|---|---|---|
| Semma Therapeutics Inc | 49.83% | 950.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc | 8.00bn | 2.98bn | 63.71bn | 8.10k | 23.18 | 7.01 | 19.88 | 7.97 | 25.83 | 25.83 | 69.32 | 85.42 | 0.5795 | 0.9149 | 3.04 | 987,419.80 | 21.62 | 17.80 | 26.89 | 20.74 | 88.21 | 92.16 | 37.30 | 25.67 | 1.82 | -- | 0.1966 | 0.00 | 17.18 | 22.77 | -10.97 | 44.30 | 5.23 | -- |
| Vertex Pharmaceuticals Incorporated | 5.40bn | 2.08bn | 68.21bn | 3.00k | 33.10 | 9.06 | 31.20 | 12.62 | 7.91 | 7.91 | 20.59 | 28.91 | 0.6264 | 3.67 | 8.60 | 1,800,895.00 | 24.13 | 5.48 | 29.32 | 6.99 | 87.71 | 87.50 | 38.51 | 9.03 | 3.60 | -- | 0.0649 | 0.00 | 36.59 | 48.30 | 119.39 | -- | 8.06 | -- |
| Zoetis Inc | 6.34bn | 1.62bn | 75.72bn | 10.60k | 47.14 | 25.38 | 36.88 | 11.94 | 3.38 | 3.38 | 13.26 | 6.28 | 0.5271 | 1.28 | 6.41 | 598,113.20 | 13.44 | 11.62 | 15.27 | 13.71 | 69.95 | 66.83 | 25.49 | 18.90 | 2.60 | 10.07 | 0.7204 | 22.90 | 7.47 | 5.52 | 8.46 | 20.80 | 20.64 | 17.02 |
| Gilead Sciences, Inc. | 22.17bn | -257.00m | 85.38bn | 11.80k | -- | 4.74 | 76.99 | 3.85 | -0.2426 | -0.2426 | 17.51 | 14.38 | 0.3722 | 4.91 | 6.73 | 1,879,153.00 | -0.4818 | 18.07 | -0.5776 | 21.88 | 78.57 | 83.42 | -1.29 | 39.31 | 2.23 | -18.13 | 0.5705 | 25.34 | 1.46 | -2.04 | -1.34 | -14.95 | 8.17 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2020 | 21.82m | 8.42% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2020 | 21.62m | 8.34% |
| The Vanguard Group, Inc.as of 31 Mar 2020 | 19.34m | 7.46% |
| BlackRock Fund Advisorsas of 31 Mar 2020 | 14.17m | 5.46% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2020 | 12.58m | 4.85% |
| SSgA Funds Management, Inc.as of 31 Mar 2020 | 11.45m | 4.42% |
| Wellington Management Co. LLPas of 31 Mar 2020 | 7.61m | 2.94% |
| Renaissance Technologies LLCas of 31 Mar 2020 | 6.86m | 2.65% |
| Capital Research & Management Co. (International Investors)as of 31 Mar 2020 | 6.54m | 2.52% |
| AllianceBernstein LPas of 31 Mar 2020 | 6.19m | 2.39% |
